ASCO 2023 | Challenges and considerations of liquid biomarker implementation in routine clinical practice

Helen Rizos, PhD, Macquarie University, Sydney, Australia, discusses the hurdles that must be surmounted before liquid biomarkers are adopted as routine clinical practice for patients with melanoma. Prof. Rizos acknowledges that clinicians must be adequately trained in order to understand the next generation sequencing (NGS) data extracted from the liquid biopsy and to determine treatment decisions based on this data. Prior to routine clinical implementation however, it’s evident that these practices must be expanded upon within a clinical trial setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.